Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Sees Significant Growth in Short Interest

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the target of a large increase in short interest in the month of February. As of February 13th, there was short interest totaling 5,585 shares, an increase of 1,201.9% from the January 29th total of 429 shares. Based on an average trading volume of 34,541 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the shares of the company are short sold. Approximately 0.1% of the shares of the company are short sold. Based on an average trading volume of 34,541 shares, the short-interest ratio is presently 0.2 days.

Institutional Trading of Matinas Biopharma

An institutional investor recently bought a new position in Matinas Biopharma stock. DRW Securities LLC purchased a new position in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned 0.72% of Matinas Biopharma as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 11.77% of the company’s stock.

Matinas Biopharma Stock Down 3.6%

NYSEAMERICAN MTNB traded down $0.02 on Wednesday, hitting $0.60. The stock had a trading volume of 13,013 shares, compared to its average volume of 32,387. The company’s 50-day moving average is $0.65 and its two-hundred day moving average is $1.19. Matinas Biopharma has a one year low of $0.47 and a one year high of $3.09. The stock has a market cap of $3.86 million, a price-to-earnings ratio of -0.18 and a beta of 1.31.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.